Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Hypoglycemia should be avoided when treating patients with diabetes. Repaglinide is an insulin secretagogue with a low hypoglycemic risk because of its rapid- and short-acting effects. However, its blood concentration has been reported to increase in combination with clopidogrel, an antiplatelet drug, and in patients with severe renal insufficiency. We herein report an elderly patient with type 2 diabetes mellitus and severe renal insufficiency who received repaglinide and hypoglycemia three days after starting clopidogrel. The concomitant use of repaglinide and clopidogrel can lead to hypoglycemia, especially in patients with severe renal insufficiency.

Citation

Kana Takayama, Kohei Fujii, Hiroki Yamaguchi, Yumika Miyoshi, Yuhei Uehara, Shimpei Nagata, Yoshinari Obata, Motohiro Kosugi, Yoji Hazama, Tetsuyuki Yasuda. Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency. Internal medicine (Tokyo, Japan). 2021;60(6):905-910

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33716254

View Full Text